UAE Biotechnology & Life Sciences Company Guide 2026: Dubai Science Park + Abu Dhabi

Updated August 2026. The UAE has made biotechnology and life sciences a national priority under Vision 2031, investing heavily in dedicated research parks, genomics infrastructure, and regulatory frameworks designed to attract global biotech companies. From Dubai Science Park (DSP) — the dedicated life sciences free zone — to Abu Dhabi’s Masdar City innovation hub and the Abu Dhabi Science and Innovation Campus (ADSIC), the UAE offers biotech companies a combination of world-class facilities, strategic GCC market access, and an improving regulatory environment for clinical trials, drug manufacturing, and gene-based research. This guide covers where to set up, what licences are required, how to navigate MOHAP and DHA R&D approvals, clinical trial requirements, and a full AED cost breakdown for 2026.

Why the UAE for Biotechnology and Life Sciences?

The UAE’s appeal as a biotech and life sciences base in 2026 rests on several structural advantages:

• Strategic geography: The UAE sits at the intersection of the GCC pharmaceutical market (valued at over USD 20 billion), the broader Middle East and North Africa (MENA) region, and Africa — providing biotech companies with a hub to serve multiple high-growth markets from a single operating base.
• Government backing: National initiatives including the UAE Genomics Program, the National Strategy for Advanced Sciences, and significant government investment in health infrastructure signal sustained political commitment to building a biotech ecosystem.
• Tax efficiency: Free zone-based biotech companies may qualify for 0% corporate tax on qualifying income under the UAE Corporate Tax Law’s Qualifying Free Zone Person rules, subject to meeting substance and income-type conditions.
• Talent pipeline: The UAE hosts Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU), Khalifa University, New York University Abu Dhabi, and other research institutions with growing biotech and biomedical programmes.
• Julphar and established industry: Julphar (Gulf Pharmaceutical Industries), the UAE’s largest pharmaceutical manufacturer based in Ras Al Khaimah, demonstrates that large-scale life sciences manufacturing is viable in the UAE, providing a benchmark and potential contract manufacturing partner for new entrants.

Dubai Science Park (DSP): The Life Sciences Free Zone

Dubai Science Park is the UAE’s purpose-built life sciences and technology free zone, developed and managed by TECOM Group (which also operates Dubai Internet City and Dubai Media City). DSP provides integrated facilities specifically designed for biotech, pharmaceutical, healthcare, and scientific research companies:

• DSP licence fee: AED 15,000–25,000 per year depending on licence type (trading, service, or industrial/manufacturing), number of permitted activities, and visa allocation.
• Lab space lease rate: AED 100–200/sqm/yr for fitted laboratory spaces within DSP’s purpose-built science buildings. Fully fitted labs with fume hoods, gas connections, and specialist ventilation are available at the higher end of this range. Office space is approximately AED 80–150/sqm/yr.
• Permitted activities: Research and development, clinical diagnostics, pharmaceutical testing, medical device development, food science, environmental testing, and biotech services are all permitted within DSP’s activity framework.
• On-site amenities: DSP provides shared analytical instrument access (HPLC, mass spectrometry, electron microscopy) through partner facilities, reducing the capital equipment requirement for early-stage companies, as well as a vibrant community of over 450 life sciences companies providing networking and partnership opportunities.

Abu Dhabi Biotech Infrastructure: Masdar City and ADSIC

Abu Dhabi’s life sciences ecosystem is anchored by two key developments:

Masdar City is a planned sustainable urban development in Abu Dhabi that hosts innovation-focused companies, research institutes, and technology ventures. Several biotech and health tech companies have established regional offices and R&D facilities in Masdar City, attracted by subsidised energy, smart infrastructure, and the Abu Dhabi government’s commitment to sustainability-linked innovation.

Abu Dhabi Science and Innovation Campus (ADSIC) is a dedicated research and innovation hub aimed at attracting global companies and research organisations to Abu Dhabi. ADSIC provides laboratory space, collaboration facilities, and access to Abu Dhabi government research grants and innovation funds. Companies establishing at ADSIC may be eligible for Ghadan 21 programme incentives, which include significant cash support for qualifying innovation activities.

G42 Healthcare — part of the G42 conglomerate backed by Abu Dhabi — is the UAE’s most prominent biotech entity. G42 Healthcare combines AI-driven drug discovery, genomics, clinical trial management, and manufacturing capabilities. For international biotech companies entering the UAE, G42 Healthcare represents both a potential partner and a competitor. G42’s Kheiron AI oncology platform and its partnership with AstraZeneca for regional clinical trials indicate the scale of biotech activity now operating from Abu Dhabi.

Clinical Trial Approval Process in the UAE

Conducting clinical trials in the UAE is increasingly attractive given the country’s diverse patient population, high-quality hospitals, and government support for clinical research. However, the approval process requires dual-track submissions:

1. MOHAP Central Research Ethics Committee (CREC): For clinical trials to be conducted at health facilities in Dubai and the Northern Emirates, or at the national level, CREC approval is required. The CREC reviews the trial protocol, informed consent documents, investigator qualifications, and insurance coverage. Fee: approximately AED 5,000–15,000 per trial protocol. Timeline: 3–9 months.
2. DHA Research Ethics Board: For trials conducted at DHA-licensed health facilities in Dubai, separate DHA REB approval is required in addition to MOHAP CREC approval. Timeline: 2–6 months, which may run in parallel with CREC review.
3. DOH Research Ethics Committee: For trials conducted at DOH-licensed facilities in Abu Dhabi. DOH REC operates independently of MOHAP CREC, and some sponsors choose to conduct Abu Dhabi trials under DOH REC approval alone for trials limited to Abu Dhabi sites.
4. Clinical Trial Agreement: A formal agreement between the sponsor (the biotech company), the Principal Investigator, and the host health institution must be executed before the trial commences. This agreement covers indemnification, IP ownership of trial data, publication rights, and adverse event reporting obligations.
5. MOHAP drug import NOC for trial investigational products: Investigational medicinal products (IMPs) imported for clinical trials require a MOHAP Special Permit, separate from the standard drug import NOC process.

Total time from protocol finalisation to first patient enrolled in the UAE is typically 6–18 months. International multi-centre trials registering in the UAE should build at least 12 months of regulatory approval time into their trial planning.

UAE Genomics Program: Research Partnership Opportunities

The Emirates Genome Authority (EGA) manages the UAE Genomics Program, which has sequenced over 1 million genomes from UAE residents — one of the world’s most diverse biobank datasets, reflecting the UAE’s population of 200+ nationalities. This dataset represents a unique research resource for biotech companies focused on:

• Population genetics and disease prevalence in non-European populations (a significant gap in global genomic databases currently dominated by European-ancestry data).
• Pharmacogenomics — identifying genetic variants affecting drug response in Middle Eastern, South Asian, and African populations.
• Rare genetic disease research — the UAE’s consanguineous Emirati population has an elevated prevalence of certain autosomal recessive disorders, creating unique research value.

Biotech companies seeking access to the UAE biobank for research collaborations must apply to EGA through a formal data access agreement, demonstrate the scientific and public health value of the proposed research, and agree to data governance terms including data residency requirements (UAE genomic data cannot be exported in identifiable form).

GMP Manufacturing in the UAE: Requirements and Free Zones

For biotech companies planning to manufacture pharmaceutical products — including biologics, vaccines, or small molecule drugs — in the UAE, Good Manufacturing Practice (GMP) compliance is mandatory:

• GMP Standards: UAE-manufactured drugs must comply with either US FDA (21 CFR Parts 210/211), EU GMP (EudraLex Vol. 4), or WHO GMP standards. MOHAP requires GMP compliance for all pharmaceutical manufacturers operating in the UAE.
• MOHAP manufacturing licence: A pharmaceutical manufacturing licence from MOHAP is required before any drug manufacturing activity can commence. This requires factory design approval, equipment qualification, validation master plans, and a MOHAP manufacturing inspection.
• Julphar (Ras Al Khaimah): Gulf Pharmaceutical Industries (Julphar) operates WHO GMP-certified manufacturing facilities in RAK producing over 90 product lines. Julphar offers contract manufacturing services for companies that need UAE-manufactured products for GCC market distribution.
• Dubai Science Park industrial licence: DSP offers an industrial/manufacturing licence for pharmaceutical manufacturers, combining the free zone’s administrative benefits with the MOHAP manufacturing licence requirements.

Biotech and Life Sciences Cost Breakdown 2026

Cost Item	AED Amount	Notes
DSP free zone licence (annual)	15,000–25,000	TECOM Group / Dubai Science Park
Lab space lease at DSP (per sqm/yr)	100–200	Fitted lab including fume hoods, gas, ventilation
MOHAP CREC clinical trial approval	5,000–15,000	Per trial protocol; DHA REB separate if Dubai sites
MOHAP drug manufacturing licence	20,000–50,000	For pharmaceutical manufacturing operations
Lab equipment (PCR, HPLC, bioreactor)	200,000–2,000,000	Scale-dependent; DSP shared facility option available
Research scientist salaries (year 1, per FTE)	120,000–300,000	PhD-level researcher; varies by specialisation
Patent filing — UAE + PCT route	15,000–40,000	UAEIPOAA filing plus international PCT application
Regulatory affairs consultancy	50,000–200,000	MOHAP dossier preparation, licensing strategy
Year 1 R&D Total (estimated)	500,000–5,000,000	Pre-manufacturing R&D stage; manufacturing adds significantly more

Intellectual Property Protection for Biotech Companies

Protecting intellectual property is critical for biotech companies operating in the UAE. The primary IP filing routes available are:

• UAEIPOAA patent filing: The UAE Intellectual Property Office and Artists’ Association (UAEIPOAA) administers UAE patent filings. UAE patents are filed under Federal Law No. 17 of 2002 on Regulations of Industrial Property of Patents, Industrial Drawings and Designs. A UAE patent provides protection in the UAE territory only.
• GCC Patent Office: The GCC Patent Office (established under the GCC Patent Regulation 1992, based in Riyadh) issues GCC patents covering all six GCC states — a single filing provides protection across Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, and Oman. This is the preferred patent route for biotech companies targeting the entire GCC market.
• PCT Route (Patent Cooperation Treaty): For biotech companies seeking global patent protection, filing via the PCT route (administered by WIPO) provides a consolidated international application that can designate 157 member countries. Total cost of a PCT application filed from the UAE: approximately AED 15,000–40,000 in official fees, plus UAE patent attorney fees.

Frequently Asked Questions

Is CRISPR or gene editing research permitted in the UAE?

Gene editing and CRISPR-based research in the UAE occupies a regulatory grey area as of August 2026. Basic laboratory research using CRISPR tools for non-human applications (cell line modification, animal model creation for disease research) is generally permissible subject to biosafety approvals and MOHAP/DHA laboratory licensing. However, clinical applications of CRISPR — particularly germline gene editing or somatic gene therapy in human patients — require explicit MOHAP ethical review and approval from the Central Research Ethics Committee (CREC). There is no specific UAE legislation on gene editing comparable to the EU’s Advanced Therapy Medicinal Products (ATMP) regulation. Companies planning CRISPR-based therapeutic development in the UAE should seek pre-application consultation with MOHAP’s Drug Control Department before committing significant resources.

What are the advantages of Dubai Science Park versus Masdar City for a biotech startup?

Dubai Science Park offers a larger, more established community of life sciences companies (450+ tenants), purpose-built laboratory infrastructure with readily available fitted lab space for immediate occupancy, and strong connectivity to Dubai’s pharma distribution and healthcare sectors. Masdar City in Abu Dhabi offers lower real estate costs, stronger government incentive programmes for qualified companies (including potential Ghadan 21 cash grants), and proximity to the G42 ecosystem and Abu Dhabi government health procurement. For a company primarily targeting Dubai-based hospital and pharma distribution customers, DSP is generally the more practical choice. For a company pursuing significant R&D partnerships with Abu Dhabi government entities or seeking large research grants, Masdar City or ADSIC may offer better access to Abu Dhabi institutional funding.

Can a free zone biotech company conduct clinical trials at UAE mainland hospitals?

Yes. A free zone-based biotech company (e.g., incorporated at Dubai Science Park) can be the sponsor of a clinical trial conducted at mainland UAE hospitals and health facilities. The company’s free zone incorporation status does not prevent it from signing clinical trial agreements with mainland hospitals, engaging mainland-based principal investigators, or importing investigational medicinal products for the trial. MOHAP CREC and DHA/DOH REB review the trial protocol based on scientific and ethical criteria, not the sponsor’s location. The biotech company’s free zone licence should include “clinical research” or “medical research” as a permitted activity to ensure compliance with free zone regulations.

How can an international biotech company access UAE genomic data from the Emirates Genome Authority?

International biotech companies can apply to the Emirates Genome Authority (EGA) for access to the UAE biobank dataset through EGA’s formal Data Access Committee (DAC) process. Applications must include a detailed research proposal demonstrating the scientific validity and public health relevance of the research, a data management plan specifying how data will be stored and protected, confirmation that analysis will be conducted within UAE-approved computational environments (EGA requires data residency — identifiable genomic data cannot be exported), ethics committee approval from the company’s home country institution or a UAE CREC approval, and a signed data access agreement with EGA. The process typically takes 3–6 months. Companies without a UAE entity may need to partner with a UAE-based research institution (e.g., MBRU, Khalifa University) to meet the data residency and ethics requirements.

What GMP standard does MOHAP require for pharmaceutical manufacturing in the UAE?

MOHAP recognises US FDA GMP (21 CFR Parts 210 and 211), European Union GMP (EudraLex Volume 4), WHO GMP guidelines, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) GMP standard as acceptable frameworks for UAE pharmaceutical manufacturing. Companies must demonstrate compliance with one of these recognised standards, typically through a current GMP certificate issued by the relevant regulatory authority (FDA Establishment Inspection Report, EU GMP certificate from a member state competent authority, or WHO GMP certification). UAE-manufactured products intended for export to other GCC states or international markets should aim for FDA or EU GMP compliance, as these are the most widely recognised internationally and will facilitate market authorisation applications in target export markets.